Evolving Paradigms in Squamous NSCLC: References

Publication
Article
Evolving ParadigmsSquamous NSCLC
Volume 1
Issue 1

  1. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013.JAMA Oncol. 2015;1:505-527.
  2. American Cancer Society Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015. 2015. /www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed July 20, 2015.
  3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer.NCCN.org. 2015; Version 7.2015
  4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases.Nat Rev Cancer.2014;14:535-546.
  5. Gandara DR, Hammerman PS, Sos ML, Lara PNJ, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.Clin Cancer Res. 2015;21:2236- 2243.
  6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol. 2004;22:2184-2191.
  7. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.J Clin Oncol.2012;30:2055-2062.
  8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Lung Cancer Screening.NCCN.org. 2015; Version 7.2016
  9. Secretan B, Straif K, Baan R, et al. A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish.Lancet Oncol.2009;10:1033-1034.
  10. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent.Int J Epidemiol.2007;36:1048-1059.
  11. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CWJ. Cigarette smoking and changes in the histopathology of lung cancer.J Natl Cancer Inst.1997;89:1580-1586.
  12. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer.Chest. 2001;120:1577-1583.
  13. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type.Cancer. 2014;120:2883-2892.
  14. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015;10:e0121323.
  15. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med. 2011;365:395-409.
  16. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2013;143:e78S-e92S.
  17. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2014;160:330-338.
  18. Tao L, Wang R, Gao YT, Yuan JM. Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study.Cancer Epidemiol Biomarkers Prev. 2013;22:2404-2411.
  19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Smoking Cessation.NCC.Norg. 2015; Version 1.2015
  20. Cancer Genome Research Network. Comprehensive genomic characterization of squamous cell lung cancers.Nature. 2012;489:519-525.
  21. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors.Sci Transl Med. 2013;5:209ra153.
  22. Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.J Clin Oncol. 2014;32:121-128.
  23. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Transl Lung Cancer Res. 2015;4:36-54.
  24. Wistuba II. Genetics of preneoplasia: lessons from lung cancer.Curr Mol Med. 2007;7:3-14.
  25. Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer.Oncologist. 2013;18:707-716.
  26. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.Nat Genet. 2009;41:1238- 1242.
  27. Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Squamousness: nextgeneration sequencing reveals shared molecular features across squamous tumor types.CellCycle. 2015;14:2355-2361.
  28. Abbas R, McColl KS, Kresak A, et al. PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.Cancer Med.2015;4:325-332.
  29. Majewski IJ, Mittempergher L, Davidson NM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.J Pathol.2013;230:270-276.
  30. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PAJ. HER2/neu expression in malignant lung tumors.Semin Oncol. 2002;29:51-58.
  31. Schildhaus HU, Nogova L, Wolf J, Buettner R. FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.Transl Lung Cancer Res. 2013;2:92-100.
  32. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.Lancet. 2009;373:1525-1531.
  33. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.Lancet. 2008;372:1809-1818.
  34. Vansteenkiste JF, Canon JL, De Braud F, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer (NSCLC): results from the phase II BASALT-1 study.J Thorac Oncol.2015;10(9):1319- 1327.
  35. Bahleda R, Dienstmann R, Adamo B, et al. Phase 1 study of JNJ-42756493, a panfibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.J ClinOncol. 2014;32:5s(suppl): abstract 2501.
  36. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.Lancet Oncol.2015;16:763-774.
  37. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity.Future Oncol. 2015;11:1307-1326.
  38. Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGEA1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.Tumori. 2014;100:60-68.
  39. Soria JC, Marabelle A, Brahmer JR, Gettinger S. Immune checkpoint modulation for non-small cell lung cancer.Clin Cancer Res. 2015;21:2256-2262.
  40. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.Nature. 2014;515:572-576.
  41. Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (antiPDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).J Clin Oncol. 2015;33(suppl): Abstract 8030.
  42. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.Lancet Oncol. 2015;16:257-265.
  43. Schildhaus HU, Schultheis AM, Ruschoff J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung.Clin Cancer Res. 2015;21:907-915.
  44. Squamous Lung Cancer Consortium (SLCC). Squamous cell carcinoma of the lung: validation of molecular signatures for prognosis. 2015. cdp.cancer.gov/scientific_programs/specs/2/squamous_cell_carcinoma.htm. Accessed August 12, 2015.
  45. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.Clin Cancer Res. 2012;18:2443-2451.
  46. Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.Lancet Oncol.2012;13:e418-e426.
  47. Tomashefski JFJ, Connors AFJ, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival.Arch Pathol Lab Med.1990;114:468-474.
  48. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung.Ann Thorac Surg.2004;78:222- 227.
  49. Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer.J Thorac Dis. 2013;5 Suppl 5:S463-S478.
  50. Oliver TG, Patel J, Akerley W. Squamous non-small cell lung cancer as a distinct clinical entity.Am J Clin Oncol. 2015;38:220-226.
  51. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.J Clin Oncol.2013;31:992-1001.
  52. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.Am J Surg Pathol. 2011;35:15-25.
  53. Gurda GT, Zhang L, Wang Y, et al. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.Clin Transl Med. 2015;4:16.
  54. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.Mod Pathol.2011;24:1348-1359.
  55. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.ModPathol. 2012;25:405-415.
  56. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.MolCancer Ther. 2012;11:2535-2540.
  57. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer. 2009;115:1723-1733.
  58. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.J Clin Oncol.2014;32:3673-3679.
  59. Ali G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.Arch Pathol Lab Med.2014;138:1449-1458.
  60. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research.J Thorac Oncol. 2008;3:125- 129.
  61. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, phase 3 trial.Lancet. 2011;378:1079-1088.
  62. Quoix E. Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer.Drugs Aging. 2011;28:885-894.
  63. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy.Lung Cancer. 2012;77:545-549.
  64. Socinski MA. Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Curr Oncol. 2014;21:e691-e703.
  65. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albuminbound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.AnnOncol. 2006;17:1263-1268.
  66. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.Clin Cancer Res. 2006;12:1317-1324.
  67. Socinski MA, Okamoto I, Hon JK, et al. Safety and efficacy analysis by histology of 24 Evolving Paradigms in Squamous NSCLC weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.Ann Oncol. 2013;24:2390-2396.
  68. Socinski MA, Langer CJ, Okamoto I, et al. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.Ann Oncol.2013;24:314-321.
  69. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.J Clin Oncol.2008;26:3543-3551.
  70. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.Cancer. 2006;107:1589-1596.
  71. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016- 3024.
  72. Kelly K, Crowley J, Bunn PAJ, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial.J Clin Oncol. 2001;19:3210-3218.
  73. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.Ann Oncol.2007;18:317-323.
  74. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med. 2002;346:92-98.
  75. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.J Clin Oncol.2003;21:3909-3917.
  76. Hoang T, Dahlberg SE, Schiller JH, Johnson DH. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.Lung Cancer. 2013;81:47-52.
  77. Liao BC, Shao YY, Chen HM, et al. Comparative effectiveness of first-line platinumbased chemotherapy regimens for advanced lung squamous cell carcinoma.Clin Lung Cancer. 2015;16:137-143.
  78. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.Ann Oncol. 2009;20:1249-1256.
  79. Treat J, Edelman MJ, Belani CP, et al. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced nonsmall cell lung cancer.Lung Cancer. 2010;70:340-346.
  80. Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.Cancer. 2013;119:2048-2060.
  81. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med. 2005;353:123-132.
  82. Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-smallcell lung cancer.J Clin Oncol. 2012;30:3516-3524.
  83. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced nonsmall-cell lung cancer.J Clin Oncol. 2010;28:5116-5123.
  84. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.Lung Cancer. 2006;52:155-163.
  85. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.J Clin Oncol. 2009;27:591-598.
  86. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.Ther Adv Med Oncol.2011;3:139-157.
  87. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Lancet Oncol. 2013;14:981-988.
  88. Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-smallcell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).J Clin Oncol.2014;32:1902-1908.
  89. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med. 2015;373:123-135.
  90. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.J Clin Oncol. 2015;33:2004-2012.
  91. Rizvi NA, Brahmer J, Ou SHI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).J Clin Oncol. 2015;33(suppl): Abstract 8032.
  92. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.J Clin Oncol. 2014;32:5s(suppl): Abstract 8112.
  93. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med.2012;366:2443-2454.
  94. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Lancet. 2014;384:665-673.
  95. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.Clin Lung Cancer. 2006;7:389-394.
  96. Medscape. FDA panel says necitumumab has benefit in NSCLC. www.medscape.com/ viewarticle/847750. Accessed August 27, 2015.
  97. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade.Science. 1996;271:1734-1736.
  98. Stinchcombe TE. Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.Med Oncol.2014;31:960.
  99. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic.Front Oncol.2014;4:385.
  100. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy.J Clin Oncol.2015;33(17):1974-1982.
  101. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.Br J Cancer. 2015;112:1421-1427.
  102. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment.Nat Rev Immunol. 2008;8:467-477.
  103. Ikeda S, Funakoshi N, Inagaki M, Shibata T. Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinoma.Acta Cytol.2006;50:423-429.
  104. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer.Clin Cancer Res. 2011;17:5247-5256.
  105. Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure.Nature. 2010;463:184-190.
  106. Hanagiri T, Shigematsu Y, Shinohara S, et al. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I nonsmall cell lung cancer.Anticancer Res. 2013;33:2123-2128.
  107. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.Ann Surg. 2002;236:785-793.
  108. Antonia SJ, Bendell JC, Taylor R, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.J Clin Oncol. 2015;33(suppl): Abstract 7503.
  109. Antonia SJ, Goldberg SB, Balmanoukian A, et al. Phase 1b study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients with advanced non-small cell lung cancer (NSCLC).J Clin Oncol.2015;33(suppl): Abstract.
  110. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer Evolving Paradigms in Squamous NSCLC 25 NOTES chemotherapy.Nat Rev Immunol.2008;8:59-73.
  111. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med. 2012;366:2455-2465.
  112. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-smallcell lung cancer.N Engl J Med.2015;372:2018-2028.
  113. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature. 2014;515:563-567.
  114. Spira AI, Park K, Mazières J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).J Clin Oncol.2015;33(suppl): Abstract 8010.
  115. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2015;16(8):897- 907.
  116. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer.Nature. 2013;500:415-421.
  117. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.J Clin Oncol.2012;30:2046-2054.
  118. Quoix E, Forget F, Papai-Szegely Z, et al. Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.J Clin Oncol. 2015;33(suppl): Abstract 3034.
  119. Nogova L, Sequist LV, Cassier PA, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.J Clin Oncol. 2014;32:5s(suppl): Abstract 8034.
  120. Paik PK, Shen R, Ferry D, et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.J Clin Oncol. 2014;32:5s(suppl): Abstract 8035.
  121. Johnson FM, Bekele BN, Feng L, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.J Clin Oncol. 2010;28:4609-4615.
Articles in this issue
Evolving Paradigms in Squamous NSCLC: Conclusion
Evolving Paradigms in Squamous NSCLC: Conclusion
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLC
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLC
Evolving Paradigms in Squamous NSCLC: References
Evolving Paradigms in Squamous NSCLC: References
Evolving Paradigms in Squamous NSCLC: Introduction
Evolving Paradigms in Squamous NSCLC: Introduction
Related Videos
Related Content
Shift to Value-Based Care Brings New Desires for EHR Capabilities

Shift to Value-Based Care Brings New Desires for EHR Capabilities

April 18th 2024
Article

A survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.

Read More

Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer

Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer

April 18th 2024
Article

During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.

Read More

The Myeloma Trial Result I Did Not See Coming

The Myeloma Trial Result I Did Not See Coming

April 17th 2024
Article

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Read More

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

April 17th 2024
Article

During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.

Read More

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

April 16th 2024
Article

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

Read More

Creating Solutions for a 'Continual State of Transition' in Cancer Care

Creating Solutions for a 'Continual State of Transition' in Cancer Care

April 15th 2024
Article

In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.

Read More